Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Liver Cancer
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- pain score
Study Overview
Brief Summary
This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and transcutaneous nerve stimulation (TENS) for pain relieving in patients with liver cancer. Patients will randomly allocated into PENS group, Tens group and control group.
Detailed Description
PENS and TENS have been reported with analgesic effect in patients with pain, including cancer pain, lower back pain, neck pain, stomachache and so on. Effect and mechanism of PENS on pain relieving has been widely researched. With additional electrical stimulation in certain frequency and intensity to conventional acupuncture, pain controlling effect has been largely enhanced. However, invasive operation limits its application and acceptability, especially on pancreatic cancer. TENS is an advanced technique generated from PENS, which is much more welcome for its noninvasive character. Further more, its analgesic effect on cancer pain has been proved by several multi-central, randomized, clinical trials.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
Participant is allocated randomly by staff A, and grouping situation is concealed; Technician (stuff B) or chargeing docotor operates PENS or TENS, or administers oral analgesic medication; Related datas are collected according to perdetermined forms by stuff C; Outcomes are assessed by stuff D.
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Primary liver cancer with pain;
- •Haven't underwent neurolytic celiac plexus block in the past 1 month;
- •With anticipatory survival of more than 3 months.
Exclusion Criteria
- •Metastatic liver cancer;
- •Can not tolerate a flat or side lying or sitting prostrate for 30 min;
- •performance score>3;
- •Who has been recruited in other clinical trial for pain relieving;
- •Who underwent radiotherapy or local radioactive seeds implantation for pain relieving in the past month;
- •Imaging diagnosed with encephalic tumor or metastasis;
- •Who with cardiac pacemaker or metal stand;
Arms & Interventions
percutaneous stimulation
PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
Intervention: PENS (Device)
transcutaneous stimulation
TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
Intervention: TENS (Device)
Control
Conventional analgesic medication is offered.
Outcomes
Primary Outcomes
pain score
Time Frame: day0 to day6
pain score assessed via visual analogue scale (VAS)
Secondary Outcomes
- quantity of analgesic medication(day0 to Day6)
- times of breakthrough pain (BTP)(day0 to day6)